美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lycia Therapeutics

30.00

+12.0066.67%

盤後：26.50-3.5000-11.67%19:59 EDT

成交量：228.72萬

成交額：6,325.94萬

市值：15.63億

市盈率：- -

高：36.49

開：28.55

低：22.19

收：18.00

52周最高：36.49

52周最低：22.19

股本：5,209.46萬

流通股本：1,470.00萬

量比：- -

換手率：15.56%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：-11.83

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Lycia Therapeutics

交易所：

NASDAQ

成立時間：

2019

員工人數：

31

公司地址：

400 East Jamie Court,Suite 200,South San Francisco,California,United States

官網：

http://www.lyciatx.com

郵編：

94080

電話：

傳真：

- -

簡介：

Lycia Therapeutics, Inc.於2019年10月24日根據特拉華州法律註冊成立。該公司是一家處於臨床階段的生物技術公司，致力於發現和開發旨在降解致病性細胞外蛋白的新型療法，初期重點關注自身免疫性疾病、炎症性疾病和過敏性疾病。利用其專有的LYTAC平台，公司開發了一系列候選療法，有望針對現有療法未能有效應對的細胞外蛋白實現深度且持久的清除。公司正通過一項旨在確立早期概念驗證（包括藥效學和生物標誌物數據）的臨床開發策略推進這些候選藥物，以評估靶點調節情況併為進入後期開發提供依據。其IgE產品管線包含旨在降解IgE以治療過敏性疾病（包括食物過敏）的候選藥物。

董事

名稱

職位

Aetna Wun Trombley

Director,Chief Executive Officer and President

Jane Pritchett Henderson

Independent Director

Laurent Fischer

Independent Director

William J. Rieflin

Chair of the Board and Independent Director

股東

名稱

職位

Aetna Wun Trombley

Director,Chief Executive Officer and President

Amy Bachrodt

Chief Financial Officer

Chin Lee

Chief Medical Officer

Sofia Touami

Chief Business Officer

Steve Staben

Chief Scientific Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/hant/stock/LYCA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LYCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","market":"US","secType":"STK","nameCN":"Lycia Therapeutics","latestPrice":30,"timestamp":1792785600000,"preClose":18,"halted":0,"volume":2287202,"hourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"delay":0,"changeRate":0.6666666666666666,"floatShares":14700000,"shares":52094559,"eps":0,"marketStatus":"休市中","change":12,"latestTime":"10-23 16:00:00 EDT","open":28.55,"high":36.4931,"low":22.19,"amount":63259421.47999,"amplitude":0.794617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1792728000000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","floatShares":14700000,"roa":"--","roe":"--","lyrEps":0,"shares":52094559,"dividePrice":0,"high":36.4931,"amplitude":0.794617,"preClose":18,"low":22.19,"week52Low":22.19,"pbRate":"-11.83","psRate":"352.39","week52High":36.4931,"institutionHeld":0,"latestPrice":30,"eps":0,"divideRate":0,"volume":2287202,"delay":0,"ttmEps":0,"open":28.55,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LYCA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LYCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LYCA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":659118750,"yearFounded":2019,"employeeNum":31,"address":"400 East Jamie Court,Suite 200,South San Francisco,California,United States","zipCode":"94080","officePhone":"(650) 392-3357"},"stockCompanyDetail":{"websiteUrl":"http://www.lyciatx.com","stockEarnings":[{"period":"1week","weight":0.6667},{"period":"ytd","weight":0.6667}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Lycia Therapeutics, Inc.於2019年10月24日根據特拉華州法律註冊成立。該公司是一家處於臨床階段的生物技術公司，致力於發現和開發旨在降解致病性細胞外蛋白的新型療法，初期重點關注自身免疫性疾病、炎症性疾病和過敏性疾病。利用其專有的LYTAC平台，公司開發了一系列候選療法，有望針對現有療法未能有效應對的細胞外蛋白實現深度且持久的清除。公司正通過一項旨在確立早期概念驗證（包括藥效學和生物標誌物數據）的臨床開發策略推進這些候選藥物，以評估靶點調節情況併為進入後期開發提供依據。其IgE產品管線包含旨在降解IgE以治療過敏性疾病（包括食物過敏）的候選藥物。","exchange":"NASDAQ","name":"Lycia Therapeutics","nameEN":"Lycia Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LYCA\",market:\"US\",,,undefined,":{"directors":[{"name":"Aetna Wun Trombley","position":"Director,Chief Executive Officer and President"},{"name":"Jane Pritchett Henderson","position":"Independent Director"},{"name":"Laurent Fischer","position":"Independent Director"},{"name":"William J. Rieflin","position":"Chair of the Board and Independent Director"}],"executives":[{"name":"Aetna Wun Trombley","position":"Director,Chief Executive Officer and President"},{"name":"Amy Bachrodt","position":"Chief Financial Officer"},{"name":"Chin Lee","position":"Chief Medical Officer"},{"name":"Sofia Touami","position":"Chief Business Officer"},{"name":"Steve Staben","position":"Chief Scientific Officer"}]}}}